Lucence Diagnostics
Lucence Presents New Data on Liquid Biopsy for Late-Stage Cancer Monitoring, Treatment Guidance
Premium
The firm shared validation data at ASCO on its LiquidHallmark assay to help guide detection and treatment decisions for late-stage cancers.
Lucence Launches US Validation Study for Liquid Biopsy in Lung Cancer
The study will recruit 200 non-small cell lung cancer patients, comparing results of the company's ctDNA testing to tissue next-generation sequencing.
Lucence, Waseda University Partner to Develop Laser-Based Liquid Biopsy Platform
The partners believe the platform, which captures high resolution images of CTCs and clusters, has potential applications in early cancer detection and disease monitoring.
Lucence Obtains CLIA Certification for Palo Alto Lab
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations
In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto.Â
Jan 27, 2020
Nov 19, 2019